Literature DB >> 30554879

The impact of carbapenem-resistant Pseudomonas aeruginosa on clinical and economic outcomes in a Chinese tertiary care hospital: A propensity score-matched analysis.

Zhihui Chen1, Ziqin Xu2, Hongmei Wu2, Le Chen2, Shengchun Gao2, Yangfang Chen3.   

Abstract

BACKGROUND: This study aimed to estimate the impact of carbapenem-resistant Pseudomonas aeruginosa (CRPA) on clinical and economic outcomes in a Chinese tertiary care hospital.
METHODS: Patients were assigned to a carbapenem-susceptible P aeruginosa group or to a CRPA group and matched using propensity score matching. In-hospital mortality, length of stay (LOS), LOS after culture, total hospital costs, daily hospital cost, and 30-day readmission were comparatively analyzed. Subgroup analysis was performed to determine the associations between the subgrouping factors and in-hospital mortality in patients with CRPA isolates.
RESULTS: Within the propensity-matched cohort, in-hospital mortality (12.6% vs 7.8%; P   =   .044), LOS (median 29.0 vs 25.5 days; P   =   .026), LOS after culture (median 18.5 vs 14.0 days; P   =   .029), total hospital costs (median $6,082.0 vs $4,954.2; P  =  .015), and daily hospital cost (median $236.1 vs $223.6; P  =  .045) were significantly higher in CRPA patients than in carbapenem-susceptible P aeruginosa patients. Subgroup analysis revealed a significant interaction between CRPA and age (P  =  .009).
CONCLUSION: Prevention and control of CRPA among hospitalized patients, especially among those over the age of 65 years, is a good measurement for the reduction of mortality and medical costs derived from CRPA infection or colonization.
Copyright © 2018 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbapenem resistance; Costs; Infection control; Outcome; Propensity score; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2018        PMID: 30554879     DOI: 10.1016/j.ajic.2018.10.025

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  5 in total

Review 1.  Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.

Authors:  Flora Cruz-López; Adrian Martínez-Meléndez; Rayo Morfin-Otero; Eduardo Rodriguez-Noriega; Héctor J Maldonado-Garza; Elvira Garza-González
Journal:  Front Cell Infect Microbiol       Date:  2022-05-20       Impact factor: 6.073

2.  Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.

Authors:  Xuemei Zhen; Cecilia Stålsby Lundborg; Xueshan Sun; Xiaoqian Hu; Hengjin Dong
Journal:  Antimicrob Resist Infect Control       Date:  2019-08-13       Impact factor: 4.887

Review 3.  The Clinical and Economic Impact of Antibiotic Resistance in China: A Systematic Review and Meta-Analysis.

Authors:  Xuemei Zhen; Cecilia Stålsby Lundborg; Xueshan Sun; Xiaoqian Hu; Hengjin Dong
Journal:  Antibiotics (Basel)       Date:  2019-08-10

4.  Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis.

Authors:  Miquel Serra-Burriel; Matthew Keys; Carlos Campillo-Artero; Antonella Agodi; Martina Barchitta; Achilleas Gikas; Carlos Palos; Guillem López-Casasnovas
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

5.  Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore.

Authors:  Jocelyn Qi-Min Teo; Cheng Yee Tang; Jie Chong Lim; Shannon Jing-Yi Lee; Si Hui Tan; Tse-Hsien Koh; James Heng-Chiak Sim; Thuan-Tong Tan; Andrea Lay-Hoon Kwa; Rick Twee-Hee Ong
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.